Bayer announces INHALE Phase III clinical study did not meet primary endpoint
Bayer (BAYRY) announced that INHALE, a global Phase III clinical study program investigating Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia, did not demonstrate superiority versus standard of care plus aerosolized placebo.
The primary endpoint, as well as secondary endpoints were similar in both treatment arms, and were therefore not met.
Amikacin Inhale is the development name of an integrated drug-device combination, consisting of a specially formulated Amikacin Inhalation Solution and a proprietary Synchronized Inhalation System with a vibrating mesh nebulizer.
The primary outcome measure was survival at day 28-32. Secondary outcome measures included pneumonia-related mortality through to day 28-32, early clinical response up to day 10, number of days on mechanical ventilation up to day 28-32, and number of intensive care unit days up to day 28-32.
Efficacy and safety analyses from this study will be published in due course. The Amikacin Inhale program is being developed through a collaboration with Nektar Therapeutics (NKTR).
NKTR closed at $49.75. It last traded at $46.50. BAYRY closed at $32.05.
To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners.
This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility